



Newbury Pharmaceutical, CEO, Lars Minor, will present the company at Økonomisk Ugebrev's Life Science Conference on 24 September 2025 in Copenhagen.

The conference brings together investors, analysts and industry experts to highlight the most exciting trends within the life science sector. The programme contains a market update plus presentations from life science companies.

Newbury will present as the first company at 14:40, 24th September.

"We are looking forward to engaging with Danish investors and to present Newbury Pharmaceuticals as part of the life science conference," says Lars Minor, CEO, Newbury Pharmaceuticals.

More information and registration for the conference can be found here:

<https://konferencer.ugebrev.dk/event/investor-konference-den-24-september/>

For more information, contact:

Lars Minor, CEO
lars.minor@newburypharma.com
Mobile: +46 72-377 3005

www.newburypharma.com

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Press Release
23 September 2025 08:30:00 CEST



Attachments

Newbury Pharmaceutical, CEO, Lars Minor, will present the company at Økonomisk Ugebrev's Life Science Conference on 24 September 2025 in Copenhagen.